LUX BIOSCIENCES
Lux Biosciences, Inc., a biotechnology company, develops medications to treat ophthalmic diseases. Its products include LX201, a silicone matrix ocular implant that enables the release of cyclosporine A to the eye for one year; Luveniq, an oral form of calcineurin inhibitor voclosporin; LX212, a bioerodible polymer implant that contains voclosporin; and LX214, a topical mixed nanomicellar formulation of voclosporin therapy for dry eyes. The company was founded in 2005 and is based in Jersey City, New Jersey.
LUX BIOSCIENCES
Industry:
Biotechnology Life Science Medical
Founded:
2005-01-01
Address:
Jersey City, New Jersey, United States
Country:
United States
Website Url:
http://www.luxbio.com
Total Employee:
11+
Status:
Active
Contact:
201-946-0551
Email Addresses:
[email protected]
Total Funding:
129.15 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF Google Font API Apache Google Maps AJAX Libraries API Apache 2.4 CPanel SSL OpenSSL
Founder
Investors List
HBM Healthcare Investments AG
HBM Healthcare Investments AG investment in Series B - Lux Biosciences
SV Health Investors
SV Health Investors investment in Series B - Lux Biosciences
Prospect Venture Partners
Prospect Venture Partners investment in Series B - Lux Biosciences
Novo Holdings
Novo Holdings investment in Series B - Lux Biosciences
Novo Holdings
Novo Holdings investment in Series A - Lux Biosciences
HBM Healthcare Investments AG
HBM Healthcare Investments AG investment in Series A - Lux Biosciences
HBM Healthcare Investments AG
HBM Healthcare Investments AG investment in Series A - Lux Biosciences
Novo Holdings
Novo Holdings investment in Series A - Lux Biosciences
Official Site Inspections
http://www.luxbio.com
- Host name: ip-221.savvy.snowsloth.com
- IP address: 50.31.6.221
- Location: Chicago United States
- Latitude: 41.8719
- Longitude: -87.6589
- Metro Code: 602
- Timezone: America/Chicago
- Postal: 60607
